A mechanistic basis and a conceptual framework for the selection and optimization of TCRs for adoptive immunotherapy are provided for the selection and optimization of TCRs for adoptive immunotherapy.
Abstract
Glypican-3 (GPC3) is a promising target in adoptive T-cell therapy for hepatocellular carcinoma (HCC). TCR-A and TCR-B are two recently identified GPC3-specific TCRs recognizing the same HLA-A*02:01-restricted epitope but displaying markedly different therapeutic efficacy. To define the determinants of productive TCR-antigen recognition, we integrated high-resolution structures of both binary pMHC and ternary TCR:pMHC complexes, biolayer interferometry, peptide mutagenesis, target-cell conjugation assays, repetitive antigen challenge (RAC) and in vivo models. Structurally, conformational permissiveness of the immunodominant GPC3(522-530) peptide within HLA-A*02:01’s groove is central for productive TCR docking, with TCR-B presenting slower association but prolonged dwell time. Functional divergence emerged during target-cell engagement and amplified under RAC conditions, where TCR-B sustained cytotoxic activity while TCR-A progressively lost function. This superior functional endurance translated into complete tumor eradication and durable responses in vivo. These findings provide a mechanistic basis and a conceptual framework for the selection and optimization of TCRs for adoptive immunotherapy.
Modifying either the affinity-related properties or the 80BB-based architecture preserved efficacy while reducing toxicity, providing potential design considerations for affinity selection and co-stimulator design in the mesothelin-targeted TCR-mimetic CAR-T platform.
Wei Du, Si-Qi Li, Shao-Mei Gan et al.· Frontiers in Immunology· 0 citations
Development of effective vaccines and targeted immunotherapies for cancer, autoimmunity, allergy, and infectious diseases requires comprehensive understanding of functionality and antigenic specificity of involved T cell clones. A major technical challenge remains the high-throughput identification of antigen-speci...
E. Egorov, V. Kriukova, I. Shagina et al.· Scientific Reports· 0 citations
The ML model (DynamiT), trained on simulation-derived structural and dynamical features extracted from 2500 time points, revealed key determinants responsible for T-cell activation with an accuracy of 73.3%.
Jaya Vasavi Pamidimukkala, Roshan Balaji, N. Bhatt et al.· 0 citations
The LINC-seq platform, LINC-seq, recovered known cognate pairs from pooled libraries at up to 95% accuracy and performed simultaneous, library-on-library deep mutational scanning of both partners, and generalizes to any receptor-ligand pair whose trans-engagement drives a reporter.
L. Liu, Seung Won Shin, Kevin M. Joslin et al.· bioRxiv· 0 citations
ABSTRACT Redirection of T lymphocytes toward cancer cells has been one of the most promising treatment concepts in oncology developed over the past years and leading to multiple regulatory approvals for both adoptive cell therapy (ACT) and T-cell-engaging bispecific (TEB) molecules. However, progress has been achieved...
M. Hofmann, F. Unverdorben, M. Pszolla et al.· mAbs· 0 citations
Public T cell receptors (TCRs) recurrently emerge across individuals in response to common pathogens, yet the structural and biophysical basis distinguishing public from private clonotypes remains incompletely defined. Here, we combine epitope mapping, single-cell TCR sequencing, and single-particle cryo-electron micro...
Caner Akıl, Y. Peng, Julia McCarthy et al.· Nature Communications· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.